Mediators of inflammation and fibrosis

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Lai, Kar Neng ^a   Tang, Sydney C W ^a   Leung, Joseph C K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adipocytes; Fibrosis; Inflammation; Mesothelium

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIALYSIS FLUID; GLUCOSE; GLUCOSE DEGRADATION PRODUCT;

ADIPOCYTE; ANGIOGENESIS; CELL TRANSFORMATION; CONFERENCE PAPER; EPITHELIUM; EPITHELIUM CELL; FIBROSIS; INFLAMMATION; INTERSTITIUM; MESENCHYME; MESOTHELIUM; MESOTHELIUM CELL; MICROVASCULATURE; OSMOSIS; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEUM CELL; PERITONITIS; PRIORITY JOURNAL; SOLUTE; ULTRAFILTRATION;

DIALYSIS SOLUTIONS; EPITHELIUM; FIBROSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; ULTRAFILTRATION;

EID: 35748951639     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Paolo N, Sacchi G. Atlas of peritoneal histology. Perit Dial Int 2000; 20(Suppl 3):S5-96.
2. Li FK, Davenport A, Robson RL, Loetscher P, Rothlein R, williams JD, et al. Leukocyte migration across human peritoneal mesothelial cells is dependent on directed chemokine secretion and ICAM-1 expression. Kidney Int 1998; 54:2170-83.
3. Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Jablokow VR, Iwatsuki S, et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980; 140:1201-03.
4. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
5. Brownlee M, Cerami A, Vlassara H. Advanced glycosylalion end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-21.
6. Nakamura S, Tachikawa T, Tobita K, Miyazaki S, Sakai S, Morita T, et al. Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients. Am J Kidney Dis 2003; 41(Suppl 1):S61-7.
7. Welten AG, Schalkwijk CG, ter Wee PM, Meijer S, van den Born J, Beeten RJ. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Peril Dial Int 2003; 23:213-21.
8. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463:260-4.
9. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GN, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
10. Jörres A. Effect of peritoneal dialysis on peritoneal cell biology: peritoneal fibroblasts. Perit Dial Int 1999; 19(Suppl 2):SJ48-52.
11. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-39.
12. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, et al. Glucose degradation products (6DP) retard remesothelialization independently of D-glucose concentration. Kidney Int 2003; 64:1854-66.
13. Yanez-Mo M, Lara-Pezzi E, Setgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348:403-13. [Erratum in: N Engl J Med 2005; 353:2827]
14. Ito T, Yorioka N, Yamamoto M, Kataoka K, Yamakido M. Effect of glucose on intercellular junctions of cultured human peritoneal mesothetial cells. J Am Soc Nephrol 2000; 11:1969-79.
15. Leung JC, Chan LY, Li FF, Tang SC, Chan KW, Chan TM, et al. Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF. Nephrol Dial Transplant 2005; 20:1336-49.
16. Lai KN, Lai KB, Chan TM, Lam CW, Li FK, Leung JCK. Changes of cytokine profile during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 35:644-52.
17. Bos HJ, van Bronswijk H, Helmerhorst TJ, Oe PL, Hoefsmit EC, Beeten RH. Distinct subpopulations of elicited human macrophages in peritoneal dialysis patients and women undergoing laparoscopy: a study on peroxidatic activity. J Leukocyte Biol 1988; 43:172-8.
18. Shostak A, Pivnik E, Gotloib L. Cultured rat mesothelial cells generate hydrogen peroxide: a new player in peritoneal defense? J Am Soc Nephrol 1996; 7:2371-8.
19. Jörres A, Topley N, Steenweg L, Muller C, Kottgen E, Gahl GM. Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 1992; 12:80-5.
20. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22:171-7.
21. Jones S, Holmes C, Krediet RT, Mackenzie RK, Faict D, Tranæus A, et al. Bicarbonate/Lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-38.
22. Mandl-Weber S, Cohen CD, Hastinger B, Kretzter M, Sitter T. Vascular endothelial growth factor production and regulation in human peritoneal mesothetial cells. Kidney Int 2002; 61:570-8.
23. Dobbie JW, Anderson JD, Hind C. Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 1994; 14(Suppl 3):S16-20.
24. Flessner MF. The effect of fibrosis on peritoneal transport. Contrib Nephrol 2006; 150:174-80.
25. Lai KN, Leung JC, Chan LY, Li FF, Tang SC, Lam MF, et al. Differentiat expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol 2004; 138:466-75.
26. Ito H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36.
27. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
28. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 2001; 50:2792-808.
29. Ogata S, Yorioka N, Nishida Y, Shao JC, Yamakida M. Expression of receptor for advanced glycation end product mRNA by human peritoneal mesothelial cells. Nephron 2000; 86:245-6.
30. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17:199-207.
31. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane, J Am Soc Nephrol 2003; 14:2109-18.
32. De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesotheliat cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21:2549-55.
33. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, et al. Advanced glycation end products cause epithetial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108:1853-63.
34. Friedman JM. Obesity in the new millennium. Nature 2000; 404:632-4.
35. Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 2004; 59: 287-304.
36. Nordfors L, Heimbürger O, Lonnqvist F, Lindholm B, Helmrich J, Schalling M, et al. Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2. Kidney Int 2000; 57: 1713-19.
37. Friedman AN. Adiposity in dialysis: good or bad? Semin Dial 2006; 19:136-40.
38. Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14:2366-72.
39. Araujo IC, Kamimura MA, Draibe S, Canziani ME, Manfredi SR, Avesani CM, et al. Nutritional parameters and mortality in incident hemodialysis patients. J Ren Nutr 2006; 16: 27-35.
40. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145:2273-82.
41. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue reteases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997; 82:4196-200.
42. Axelsson J, Rashid Qureshi A, Suliman ME, Honda H, Pecoits-Filho R, Heimbürger O, et al. Truncal fat mass as a contributor to inflammation in end-stage renal failure. Am J Clin Nutr 2004; 80:1222-9.
43. Leung JC, Chan LY, Tang SC, Chu KM, Lai KN. Leptin induces TGF-β synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney Int 2006; 69:2078-86.